

The American College of Radiology, with more than 30,000 members, is the principal organization of radiologists, radiation oncologists, and clinical medical physicists in the United States. The College is a nonprofit professional society whose primary purposes are to advance the science of radiology, improve radiologic services to the patient, study the socioeconomic aspects of the practice of radiology, and encourage continuing education for radiologists, radiation oncologists, medical physicists, and persons practicing in allied professional fields.

The American College of Radiology will periodically define new practice guidelines and technical standards for radiologic practice to help advance the science of radiology and to improve the quality of service to patients throughout the United States. Existing practice guidelines and technical standards will be reviewed for revision or renewal, as appropriate, on their fifth anniversary or sooner, if indicated.

Each practice guideline and technical standard, representing a policy statement by the College, has undergone a thorough consensus process in which it has been subjected to extensive review, requiring the approval of the Commission on Quality and Safety as well as the ACR Board of Chancellors, the ACR Council Steering Committee, and the ACR Council. The practice guidelines and technical standards recognize that the safe and effective use of diagnostic and therapeutic radiology requires specific training, skills, and techniques, as described in each document. Reproduction or modification of the published practice guideline and technical standard by those entities not providing these services is not authorized.

Revised 2005 (Res. 7)*

PRACTICE GUIDELINE FOR THE PERFORMANCE OF PEDIATRIC AND ADULT CEREBROVASCULAR MAGNETIC RESONANCE ANGIOGRAPHY (MRA)

PREAMBLE

These guidelines are an educational tool designed to assist practitioners in providing appropriate radiologic care for patients. They are not inflexible rules or requirements of practice and are not intended, nor should they be used, to establish a legal standard of care. For these reasons and those set forth below, the American College of Radiology cautions against the use of these guidelines in litigation in which the clinical decisions of a practitioner are called into question.

The ultimate judgment regarding the propriety of any specific procedure or course of action must be made by the physician or medical physicist in light of all the circumstances presented. Thus, an approach that differs from the guidelines, standing alone, does not necessarily imply that the approach was below the standard of care. To the contrary, a conscientious practitioner may responsibly adopt a course of action different from that set forth in the guidelines when, in the reasonable judgment of the practitioner, such course of action is indicated by the condition of the patient, limitations of available resources, or advances in knowledge or technology subsequent to publication of the guidelines. However, a practitioner who employs an approach substantially different from these guidelines is advised to document in the patient record information sufficient to explain the approach taken.

The practice of medicine involves not only the science, but also the art of dealing with the prevention, diagnosis, alleviation, and treatment of disease. The variety and complexity of human conditions make it impossible to always reach the most appropriate diagnosis or to predict with certainty a particular response to treatment. Therefore, it should be recognized that adherence to these

guidelines will not assure an accurate diagnosis or a successful outcome. All that should be expected is that the practitioner will follow a reasonable course of action based on current knowledge, available resources, and the needs of the patient to deliver effective and safe medical care. The sole purpose of these guidelines is to assist practitioners in achieving this objective.

I. INTRODUCTION

This guideline was revised collaboratively by the American College of Radiology (ACR), the American Society of Neuroradiology (ASNR), the American Society of Interventional and Therapeutic Neuroradiology (ASITN), and the Society of Interventional Radiology (SIR).

Cerebrovascular magnetic resonance angiography (MRA) is a proven and useful tool for the evaluation, assessment of severity, and follow-up of diseases of the cerebrovascular system. MRA is a rapidly evolving technology. Consequently, only general recommendations can be made regarding imaging techniques. Detailed imaging protocols have been omitted here to avoid promoting obsolete methodology.

Cerebrovascular MRA should be performed only for a valid medical reason. Additional or specialized pulse sequences are frequently required to optimize the examination. While it is not possible to detect all abnormalities by using cerebrovascular MRA, adherence to the following guideline will enhance the probability of their detection.

MRA has important attributes that make it valuable in the assessment of vascular disease. Compared to radiographic catheter-based angiography, it is noninvasive with no risk of neurologic deficit, circulatory compromise due to vascular injury, or adverse effects of iodinated contrast material. Compared to vascular ultrasound, it is less operator-dependent, has greater freedom from interference by body habitus, and has greater three-dimensional capability.

Children demonstrate a different spectrum of disease than do adults, and the routine protocols used for evaluating the adult patient may not be optimal or even appropriate in evaluating children. As the brain and the cerebrovascular system develop during infancy and childhood, cerebrovascular MRA can provide valuable information regarding flow conditions and pathologic processes within the brain and spine. However, technical and safety issues are more complex in pediatric patients. The smaller size of the pediatric patient increases the demand for higher resolution. In addition, sedation is frequently required to successfully complete the examination.

Application of this guideline should be in accordance with the [ACR Practice Guideline for Performing and Interpreting Magnetic Resonance Imaging \(MRI\)](#), the [ACR Practice Guideline for Pediatric Sedation/Analgesia](#), and the [ACR Practice Guideline for Adult Sedation/Analgesia](#).

II. QUALIFICATIONS AND RESPONSIBILITIES OF PERSONNEL

See the [ACR Practice Guideline for Performing and Interpreting Magnetic Resonance Imaging \(MRI\)](#).

III. INDICATIONS

A. Pediatric Indications for Cerebrovascular MRA

MRA is particularly applicable in children due to the risk (albeit low) related to angiographic procedures. Various studies of children with strokes that compared MRA to conventional angiography found MRA to be 1) accurate in the delineation of stenosis and/or occlusion, and 2) able to demonstrate collateral vascular anatomy. Indications for cerebrovascular MRA for children include, but are not limited to, the definition and evaluation of the following:

1. Arterial dissection.
2. Dural sinus thrombosis.
3. Cerebral arteriovenous malformations.
4. Vascular status following extracorporeal membrane oxygenation.
5. Intracranial aneurysm.
6. Vascular abnormalities associated with sickle cell anemia.

7. Blood supply to vascular neoplasms for operative planning.
8. Etiology of intracranial hemorrhage and spinal hemorrhage.
9. Presence, nature, and extent of injury to cervicocerebral vessels, including dissection.
10. Presence of intracranial venous occlusive disease and spinal venous drainage.
11. Nature and extent of other congenital or acquired vascular abnormality.

B. Indications for cerebrovascular MRA of adults include, but are not limited to, the definition and evaluation of the following:

1. Presence and extent of atherosclerotic occlusive disease and thromboembolic phenomena.
2. Etiology of intracranial hemorrhage and spinal hemorrhage.
3. Relevant vascular anatomy for determining the effect of therapeutic measures including post-treatment evaluation of endovascular treatment of aneurysm and arteriovenous malformation (AVM) ablation.
4. Presence, location, and anatomy of extracranial and intracranial aneurysms and vascular malformations.
5. Presence, nature, and extent of injury to cervicocerebral vessels, including dissection.
6. Vascular supply to tumors.
7. Presence of intracranial venous occlusive disease and spinal venous drainage.
8. Nature and extent of other congenital or acquired vascular abnormality.

C. Evaluation of the aortic arch and subclavian arteries in adults and children may require separate techniques and sequences. Indications include, but are not limited to, the following:

1. Dissection of the aorta and great vessels to the brain
2. Aneurysm of the aorta and/or its branches, and subclavian steal
3. Differentiation of aneurysms and masses
4. Definition of the relationship of masses to nearby vascular structures
5. Identification of congenital abnormalities of the aorta, such as coarctation, double arch, and aberrant subclavian artery
6. Evaluation of superior vena cava syndrome or unilateral upper extremity edema

IV. SAFETY GUIDELINES AND POSSIBLE CONTRAINDICATIONS

See the [ACR Practice Guideline for Performing and Interpreting Magnetic Resonance Imaging \(MRI\)](#) and the ACR White Paper on Magnetic Resonance Safety¹.

Peer-reviewed literature pertaining to MR safety should be reviewed on a regular basis [53,55].

V. SPECIFICATIONS OF THE EXAMINATION

The supervising physician must have complete understanding of the indications, risks, and benefits of the examination, as well as alternative imaging procedures. The physician must be familiar with potential hazards associated with MRI, including potential adverse reactions to contrast media. The physician should be familiar with relevant ancillary studies that the patient may have undergone. The physician performing MRI interpretation must have a clear understanding and knowledge of the anatomy and pathophysiology relevant to the MRI examination.

The written or electronic request for MRA should provide sufficient information to demonstrate the medical necessity of the examination and allow for its proper performance and interpretation.

Documentation that satisfies medical necessity includes 1) signs and symptoms and/or 2) relevant history (including known diagnoses). Additional information regarding the specific reason for the examination or a provisional diagnosis would be helpful and may at times be needed to allow for the proper performance and interpretation of the examination.

The request for the examination must be originated by a physician or other appropriately licensed health care provider. The accompanying clinical information should be provided by a physician or other appropriately licensed health care provider familiar with the patient's clinical problem or question and consistent with the state's scope of practice requirements. (ACR Resolution 35, adopted in 2006)

The supervising physician must also understand the pulse sequences to be employed and their effect on the appearance of the images, including the potential generation of image artifacts. Standard imaging protocols may be established and varied on a case-by-case basis when necessary. These protocols should be reviewed and updated periodically.

¹In 2007 the following updated version was published: ACR Guidance Document for Safe MR Practices. AJR 2007;188:1-27.

A. Patient Selection

The physician responsible for the examination shall supervise patient selection and preparation, and be available in person or by phone for consultation. Patients shall be screened and interviewed prior to the examination to exclude individuals who may be at risk by exposure to the MR environment.

Certain indications require administration of intravenous (IV) contrast media. IV contrast enhancement should be performed using appropriate injection protocols and in accordance with the institution's policy on IV contrast utilization. (See the [ACR Practice Guideline for the Use of Intravascular Contrast Media](#).)

Patients suffering from anxiety or claustrophobia may require sedation or additional assistance. Administration of moderate sedation may enable achievement of the examination success. If moderate sedation is necessary, refer to the [ACR Practice Guideline for Adult Sedation/Analgesia](#) or the [ACR Practice Guideline for Pediatric Sedation/Analgesia](#).

B. Facility Requirements

Appropriate emergency equipment and medications must be immediately available to treat adverse reactions associated with administered medications. The equipment and medications should be monitored for inventory and drug expiration dates on a regular basis. The equipment, medications, and other emergency support must also be appropriate for the range of ages and sizes in the patient population.

C. Examination Technique

Magnetic resonance angiography is a general term that refers to a diverse group of MR pulse sequences. Three different mechanisms can be used to generate signal from flowing blood. The most common method, called time of flight (TOF), relies on inflow enhancement to generate images of blood flow. Flow images and quantitative measurements of flow velocity can be obtained using phase-contrast (PC) MRA methods in which the image contrast is generated by velocity-induced phase shifts. A third method relies on enhancement of the blood signal by paramagnetic contrast agents and employs rapid, three-dimensional (3D) T1-weighted gradient echo acquisitions. Individuals using MRA shall understand the artifacts and limitations of 2D TOF, 3D TOF, 2D or 3D PC, and contrast-enhanced 3D TOF imaging techniques. In certain instances, such as atherosclerotic disease of the arch, directional images or time resolved acquisition should be obtained.

1. Non-contrast TOF MRA

The most commonly used inflow techniques are 2D TOF and 3D TOF. In 2D TOF acquisitions, multiple thin slices are obtained and combined to form a three-dimensional data set. Vascular structures are isolated from the surrounding tissue by selecting the pixels with maximum intensity. The 3D TOF technique directly acquires a three-dimensional volume. The vascular structures are delineated by selecting the pixels with maximum intensity.

The MRA data sets are also displayed as two dimensional source images. The supervising physician should review the source images to reduce possible confusion of high signal material (e.g., fat) with flow signal. Review of the source images also aids diagnosis by eliminating overlapping structures and determining if artifacts are the cause of spurious signal or signal loss.

MRA data are routinely postprocessed using a maximum-intensity projection (MIP) reconstruction algorithm. Rotating displays of three-dimensional data sets allow separation of vessels that are superimposed on routine projections. The supervising physician shall be familiar with MIP, surface display, volume display, and multiplanar reformatting techniques, and with the limitations and strengths of each method. The type and frequency of artifacts will vary with the display technique; thus, the supervising physician must understand the potential errors with each display method.

2. Contrast-enhanced TOF MRA

Contrast-enhanced 3D TOF MRA combines a fast T1-weighted gradient echo acquisition with an intravenously administered paramagnetic contrast agent. Such agents reduce T1 relaxation time of blood and nearly eliminate the loss of signal related to saturation effects, thus leading to a more accurate assessment of stenosis. MRA with contrast enhancement has been evaluated for use in assessing the cervical carotid arterial system, the vertebrobasilar system, the dural venous sinuses, and the ascending and descending thoracic aorta. MRA with contrast has been successful in demonstrating atherosclerotic occlusive disease, dissection of the aorta, anomalies of the aortic arch, and vascular involvement by tumor. MRA with contrast does not require cardiac gating and is, therefore, more widely applicable in patients with irregular cardiac rhythms. Furthermore, respiratory artifacts are eliminated by breath holding, and artifacts due to flow-related

enhancement are not encountered. These advantages make MRA with contrast extremely useful for imaging of the aortic arch and great vessels.

Contrast-enhanced cerebrovascular MRA is optimized when the center of k space is sampled during the peak arterial concentration of the gadolinium chelate. Elliptical centric encoding is an example of a technique that improves capture of the arterial phase of the bolus and reduces venous contamination of the image.

When using elliptical centric encoding, ringing artifacts occur when the center of k space is sampled while the concentration of contrast material is rapidly changing. The ringing artifacts are manifested in the image as linear regions of signal loss. By recessing the center of k space a few seconds from the arrival of the bolus, ringing artifacts can be reduced.

The concentration of contrast should be relatively constant during the acquisition. An injection rate of 2 to 3 mL/sec generates a bolus profile with a 5 to 7 second arterial phase which is desirable because most techniques require several seconds to sample the center of k space. The injection volume may vary based on the size of the patient. A common practice is to use 30 to 40 mL of a gadolinium chelate for the majority of adult patients. For very large patients the volume of contrast may need to be increased to offset the effects of contrast dilution in the blood pool. The use of a power injector facilitates control of the injection rate and helps to standardize the protocol. Following injection of the contrast material, the power injector can rapidly switch to inject the saline flush. The injection rate and dose of contrast material will need to be adjusted for pediatric patients.

Imaging of the cerebrovascular system is particularly challenging due to the roughly 10 second circulation times within the brain. Arch and carotid cerebrovascular MRA studies require very accurate timing of the acquisition in relation to the contrast injection. If the images are obtained too early, the arterial structures may not be visualized. Late acquisition will result in reduced arterial signal, venous opacification, and enhancement of the soft tissues. Ideally the center of k space is scanned during the first pass of the bolus.

A limitation of contrast-enhanced TOF MR angiography is that the extracellular gadolinium chelates are nonspecific MR contrast agents.

Many normal and pathologic tissues will enhance. This makes repeat imaging more problematic. Subtraction techniques may help, but often there is incomplete subtraction of the background, and artifacts are generated due to misregistration of the data sets. The high-signal-intensity enhanced stationary tissue will obscure vessels in the maximum intensity projection (MIP) images and may simulate flow signal pattern or degrade vessel detail.

Saturation (SAT) bands are less effective when the T1 of blood is significantly reduced. Venous structures such as the internal jugular vein cannot be eliminated from the MR angiogram by the selective placement of SAT bands and may obscure the carotid bifurcation. Similarly, arterial structures cannot be selectively eliminated by saturation techniques when contrast material is administered.

3. Phase contrast (PC) MRA

PC MRA is the third general category of MRA techniques. The PC data can be obtained as - either a two-dimensional or three-dimensional dataset. Contrast enhancement may also be employed to increase the signal obtained from blood. PC techniques are based on the physical properties of moving spins. As protons move through a magnetic field, they acquire a phase shift directly proportional to their velocity. The magnitude of the phase shift can be measured, and an image of the flowing blood can be generated. Display of the vessels is similar to that obtained with the TOF technique, although direction of flow can also be indicated. In some instances, it is necessary to gate the PC acquisition to the cardiac cycle to measure flow velocity or flow volume. Peripheral or cardiac gating should be available.

VI. DOCUMENTATION

Reporting should be in accordance with the [ACR Practice Guideline for Communication of Diagnostic Imaging Findings](#).

In addition to examining the vascular structures of interest, the MR source images should be examined for extravascular abnormalities that may have clinical relevance. These abnormalities should be described in the formal report of the examination.

VII. EQUIPMENT SPECIFICATIONS

The MR equipment specifications and performance shall meet all state and federal requirements. These

requirements include, but are not limited to, specifications of maximum static magnetic field strength, maximum rate of change of the magnetic field strength (dB/dt), maximum radiofrequency power deposition (specific absorption rate), and maximum acoustic noise levels.

A workstation capable of creating multiplanar reformations, maximum intensity projections, and volume renderings or shaded surface displays is required for most MR angiograms. The workstation should also allow the direct measurement of vascular diameters and, when appropriate, path lengths and branch angles either from source images or from reformatted images.

VIII. QUALITY CONTROL AND IMPROVEMENT, SAFETY, INFECTION CONTROL, AND PATIENT EDUCATION

Policies and procedures related to quality, patient education, infection control, and safety should be developed and implemented in accordance with the ACR Policy on Quality Control and Improvement, Safety, Infection control, and Patient Education appearing elsewhere in the ACR Practice Guidelines and Technical Standards book.

Specific policies and procedures related to MRI safety should be in place with documentation that is updated annually and compiled under the supervision and direction of the supervising MRI physician. Guidelines should be provided that deal with potential hazards associated with the MRI examination of the patient as well as to others in the immediate area [50,53,55,56]. Screening forms must also be provided to detect those patients who may be at risk for adverse events associated with the MRI examination [50,53,55,56].

Equipment performance monitoring should be in accordance with the [ACR Technical Standard for Diagnostic Medical Physics Performance Monitoring of Magnetic Resonance Imaging \(MRI\) Equipment](#).

ACKNOWLEDGEMENTS

This guideline was revised as described in the ACR Practice Guidelines and Technical Standards book by the ACR Guidelines and Standards Committee of the Commission on Neuroradiology in collaboration with the American Society of Neuroradiology (ASNR), the American Society of Interventional and Therapeutic Neuroradiology (ASITN), and the Society of Interventional Radiology (SIR).

Principal Reviewer: Patrick A. Turski, MD

ACR Guidelines and Standards Committee

Neuroradiology

Body MRI

Co-Chairs

Suresh K. Mukherji, MD	Jeffrey Brown, MD
John D. Barr, MD	David A. Bluemke, MD
John J. Connors, III, MD	Jerry W. Froelich, MD
John E. Jordan, MD	Michael L. Lipton, MD
Emanuel Kanal, MD	Colin S. Poon, MD, PhD
Stephen A. Kieffer, MD	Donald J. Schnapf, DO
Eric J. Russell, MD	Frank G. Shellock, PhD
Sanjay K. Shetty, MD	Cynthia S. Sherry, MD
Charles L. Truwit, MD	Barry Stein, MD
Patrick A. Turski, MD	Paul T. Weatherall, MD
Robert C. Wallace, MD	
Wade H. Wong, DO	
William G. Bradley, MD, Chair, Commission	

Comments Reconciliation Committee

Peter H.B. McCreight, MD, Chair, CSC
William G. Bradley, Jr., MD, PhD
Jeffrey J. Brown, MD
Paul A. Larson, MD
Suresh K. Mukherji, MD
David A. Rubin, MD
Charles L. Truwit, MD
Patrick A. Turski, MD
Gilbert L. Vezina, MD

REFERENCES

1. Adamis MK, Li W, Wielopolski PA, et al. Dynamic contrast-enhanced subtraction MR angiography of the lower extremities: initial evaluation with a - multisection, two-dimensional, time-of-flight sequence. *Radiology* 1995;196:689-695.
2. Anderson CM, Saloner D, Tsuruda JS, et al. Artifacts in maximum-intensity-projection display of MR angiograms. *AJR* 1990;154:623-629.
3. Anson J, Crowell RM. Cervicocranial arterial dissection. *Neurosurgery* 1991;29:89-96.
4. Barger AV, Peters DC, Block WF, et al. Phase contrast with interleaved undersampled projections. *Magn Reson Med* 2000;43:503-509.
5. Barnett HJ, Taylor DW, Eliasziw M, et al. Benefit of carotid endarterectomy in patients with symptomatic moderate or severe stenosis. *N Eng J Med* 1998; 339:1415-1425.
6. Bernstein MA, Huston J III, Lin C, et al. High-resolution intracranial and cervical MRA at 3.0T: technical considerations and initial experience. *Magn Reson Med* 2001;46:955-962.
7. Carr JC, Ma J, Desphande V, et al. High-resolution breath-hold contrast-enhanced MR angiography of the entire carotid circulation. *AJR* 2002;178:543-549.
8. Colletti PM. Magnetic resonance procedures and pregnancy. In: Shellack FD, ed. *Magnetic Resonance Procedures: Health Effects and Safety*. Boca Raton, Fla: CRC Press; 2001.
9. Demaerel P, Marchal G, Casteels I, et al. Intracavernous aneurysm: superior demonstration by magnetic resonance angiography. *Neuroradiology* 1990;32:322-324.
10. De Marco JK, Nesbit GM, Wesbey GE, et al. Prospective evaluation of extracranial carotid stenosis: MR angiography with maximum-intensity projections and multiplanar reformation compared with conventional angiography. *AJR* 1994;163:1205-1212.
11. Earls JP, Rofsky NM, DeCorato DR, et al. Breath-hold single-dose, gadolinium-enhanced three-dimensional MR aortography: usefulness of a timing examination and MR power injector. *Radiology* 1996;201:705-710.
12. Edelman RR, Hesselink J. *Clinical Magnetic Resonance Imaging*. 3rd edition. Chapter 25. Philadelphia, Pa: WB Saunders Co; 2004.
13. Edelman RR, Wentz KU, Mattle HP, et al. Intracerebral arteriovenous malformations: evaluation with selective MR angiography and venography. *Radiology* 1989;173:831-837.
14. Fellner FA, Fellner C, Wutke R, et al. Fluoroscopically triggered contrast-enhanced 3D MR DSA and 3D time-of-flight turbo MRA of the carotid arteries: first clinical experience in correlation with ultrasound, X-ray angiography, and endarterectomy findings. *Magn Reson Imaging* 2000;18:575-585.
15. Foo TK, Saranathan M, Prince MR, et al. Automated detection of bolus arrival and initiation of data acquisition in fast, three-dimensional, gadolinium-enhanced MR angiography. *Radiology* 1997;203:275-280.
16. Hennig J, Scheffler K, Laubenberger J, et al. Time-resolved projection angiography after bolus injection of contrast agent. *Magn Reson Med* 1997;37:341-345.
17. Holland GA, Dougherty L, Carpenter JP, et al. Breath-hold ultrafast three-dimensional gadolinium-enhanced MR angiography of the aorta and the renal and other visceral abdominal arteries. *AJR* 1996; 166:971-981.
18. Husson B, Lasjaunias P. Radiological approach to disorders of arterial brain vessels associated with childhood arterial stroke: a comparison between MRA and contrast angiography. *Pediatr Radiol* 2004; 34:2-4.
19. Huston J III, Fain SB, Riederer SJ, et al. Carotid arteries: maximizing arterial to venous contrast in fluoroscopically triggered, contrast-enhanced MR angiography with elliptic centric view ordering. *Radiology* 1999;211:265-273.
20. Kauczor HU, Layer G, Schad LR, et al. Clinical applications of MR angiography in intrathoracic masses. *J Comput Assist Tomogr* 1991;15:409-417.

21. Kent KC, Kuntz KM, Patel MR, et al. Perioperative imaging strategies for carotid endarterectomy: an analysis of morbidity and cost-effectiveness in symptomatic patients. *JAMA* 1995;274:888-893.
22. Kido DK, Barsotti JB, Rice LZ, et al. Evaluation of the carotid artery bifurcation: comparison of magnetic resonance angiography and digital subtraction arch aortography. *Neuroradiology* 1991;33:48-51.
23. Kido DK, Panzer RJ, Szumowski J, et al. Clinical evaluation of stenosis of the carotid bifurcation with magnetic resonance angiographic techniques. *Arch Neurol* 1991;48:484-489.
24. Korosec FR, Frayne R, Grist M, et al. Time-resolved contrast-enhanced 3-dimensional MR angiography. *Magn Reson Med* 1996;36:345-351.
25. Korosec FR, Weber DM, Mistretta CA, et al. A data adaptive reprojection technique for MR angiography. *Magn Reson Med* 1992;24:262-274.
26. Latchaw RE, Yonas H, Hunter GJ, et al. Guidelines and recommendations for perfusion imaging in cerebral ischemia. *Stroke* 2003;34:1084-1104.
27. Lauffer RB, Parmelee DJ, Ouellet HS, et al. MS-325: a small-molecule vascular imaging agent for magnetic resonance imaging. *Acad Radiol* 1996; 3:S356-S358.
28. Leung DA, McKinnon GC, Davis CP, et al. Breath-hold, contrast-enhanced, three-dimensional MR angiography. *Radiology* 1996;200:569-571.
29. Maki JH, Prince MR, Londy FJ, et al. The effects of time-varying intravascular signal intensity and k-space acquisition order on three-dimensional MR angiography image quality. *J Magn Reson Imaging* 1996;6:642-651.
30. Masaryk TJ, Ross JS, Modic MT, et al. Carotid bifurcation: MR imaging: work in progress. *Radiology* 1988;166:461-466.
31. Mattle HP, Wentz KU, Edelman RR, Wallner B, et al. Cerebral venography with MR. *Radiology* 1991; 178:453-458.
32. Mulligan SA, Matsuda T, Lanzer P, et al. Peripheral arterial occlusive disease: prospective comparison of MR angiography and color duplex ultrasound with conventional angiography. *Radiology* 1991;178:695-700.
33. Nussel F, Wegmuller H, Huber P. Comparison of magnetic resonance angiography, magnetic resonance imaging, and conventional angiography in cerebral arteriovenous malformation. *Neuroradiology* 1991; 33:56-61.
34. Ozsarlak O, Van Goethem JW, Maes M, et al. MR angiography in steno-occlusive disease of the intracranial vessels. *Br J Radiol* 2003;86:354-356.
35. Padayachee TS, Bingham JB, Graves MJ, et al. Dural sinus thrombosis: diagnosis and follow-up by magnetic resonance angiography imaging. *Neuroradiology* 1991;33:165-167.
36. Parker DL, Goodrich KC, Alexander AL, et al. Optimized visualization of vessels in contrast-enhanced intracranial MR angiography. *Magn Reson Med* 1998;40:873-882.
37. Phan T, Huston J III, Bernstein MA, et al. Contrast-enhanced magnetic resonance angiography of the cervical vessels: experience with 422 patients. *Stroke* 2001;32:2282-2286.
38. Pollock BE, Gorman DA, Brown PD. Radiosurgery for arteriovenous malformations of the basal ganglia, thalamus, and brainstem. *J Neurosurg* 2004;100:210-214.
39. Prince MR, Grist TM, Debatin JF. *3D Contrast MR Angiography*. 3rd edition. Berlin, Germany: Springer-Verlag; 2003.
40. Prince MR, Yucel EK, Kaufman JA, et al. Dynamic gadolinium-enhanced three-dimensional abdominal MR arteriography. *J Magn Reson Imaging* 1993;3:877-881.
41. Prince MR. Body MR angiography with gadolinium contrast agents. *Magn Reson Imaging Clin N Am* 1996;4:11-24.
42. Prince MR, Narasimham DL, Stanley JC, et al. Breath-hold gadolinium-enhanced MR angiography of the abdominal aorta and its major branches. *Radiology* 1995;197:785-792.
43. Remonda L, Senn P, Barth A, et al. Contrast-enhanced 3D MR angiography of the carotid artery: comparison with conventional digital subtraction angiography. *AJNR* 2002;23:213-219.
44. Rezaei AR, Finelli D, Nyenhuis JA, et al. Neurostimulation systems for deep brain stimulation: in vitro evaluation of MRI-related heating at 1.5 Tesla. *J Magn Reson Imaging* 2002;15:241-250.
45. Rezaei AR, Phillips M, Baker KB, et al. Neurostimulation system used for deep brain stimulation (DBS): MR safety issues and implications of failing to follow safety recommendations. *Invest Radiol* 2004;39:300-303.
46. Riederer SJ, Tasciyan T, Farzaneh F, et al. MR fluoroscopy: technical feasibility. *Magn Reson Med* 1988;8:1-15.
47. Rippe DJ, Grist TM, Uglietta JP, et al. Carotid body tumor: flow-sensitive pulse sequences and MR angiography. *J Comput Assist Tomogr* 1989;13:874-877.
48. Ruggieri PM, Masaryk TJ, Ross JS, et al. Magnetic resonance angiography of the intracranial vasculature. *Top Magn Reson Imaging* 1991;3:23-33.
49. Runge VM. Safety of MR contrast agents. In: Shellock, FG, ed. *Magnetic Resonance Procedures: Health Effects and Safety*. Boca Raton, Fla: CRC Press; 2001.
50. Sawyer-Glover AM, Shellock FG. Pre-MRI procedure screening: recommendations and safety considerations for biomedical implants and devices. *J Magn Reson Imaging* 2000;12:92-106.

51. Schwickert HC, Roberts TP, Muhler A, et al. Angiographic properties of Gd-DTPA-24-cascade-polymer: a new macromolecular MR contrast agent. *Eur J Radiol* 1995;20:144-150.
52. Sevick RJ, Tsuruda JS, Schmalbrock P. Three-dimensional time-of-flight MR angiography in the evaluation of cerebral aneurysms. *J Comput Assist Tomogr* 1990;14:874-881.
53. Shellock FG, Crues JV. Invited review – MR procedures: biologic effects, safety, and patient care. *Radiology* 2004;232:635-652.
54. Shellock FG. Biomedical implants and devices: assessment of magnetic field interactions with a 3.0 Tesla MR system. *J Magn Reson Imaging* 2002;16:721-732.
55. Shellock FG. *Reference Manual for Magnetic Resonance Safety, Implants, and Devices*. 2005 edition. Los Angeles, Calif: Biomedical Research Publishing Group; 2005.
56. Shellock FG. *Magnetic Resonance Procedures: Health Effects and Safety*. Boca Raton, Fla: CRC Press; 2001.
57. Shellock FG, Kanal E. Safety of magnetic resonance imaging contrast agents. *J Magn Reson Imaging* 1999;10:477-484.
58. Snidow JJ, Johnson MS, Harris VJ, et al. Three-dimensional gadolinium-enhanced MR angiography for aortoiliac inflow assessment plus renal artery screening in a single breath hold. *Radiology* 1996;198:725-732.
59. Stillman AE, Wilke N, Li D, et al. Ultra-small superparamagnetic iron oxide to enhance MRA of the renal and coronary arteries: studies in human patients. *J Comput Assist Tomogr* 1996;20:51-55.
60. Vanderzant C, Bromberg M, MacGuire A, et al. Isolated small-vessel angiitis of the central nervous system. *Arch Neurol* 1988;45:683-687.
61. Van Grimberge F, Dymarkowski S, Budts W, et al. Role of magnetic resonance in the diagnosis of subclavian steal syndrome. *J Magn Reson Imaging* 2000;12:339-342.
62. Vidailhet M, Piette JC, Wechsler B, et al. Cerebral venous thrombosis in systemic lupus erythematosus. *Stroke* 1990;21:1226-1231.
63. Vock P, Terrier F, Wegmuller H, et al. Magnetic resonance angiography of abdominal vessels: early experience using the three-dimensional phase-contrast technique. *Br J Radiol* 1991;64:10-16.
64. Wang Y, Johnston DV, Breen JF, et al. Dynamic MR digital subtraction angiography using contrast enhancement, fast data acquisition, and complex subtraction. *Magn Reson Med* 1996;36:551-556.
65. Watts R, Wang Y, Redd B, et al. Recessed elliptical-centric view-ordering for contrast enhanced 3D MR angiography of the carotid arteries. *Magn Reson Med* 2002;48:419-424.
66. Wesbey G. Flow phenomena, classification, and clinical aspects of magnetic resonance angiography. *Curr Opin Radiol* 1991;3:188-195.
67. Willig DS, Turski PA, Frayne R, et al. Contrast-enhanced 3-dimensional MR DSA of the carotid artery bifurcation: preliminary study of comparison with unenhanced 2-dimensional and 3-dimensional time-of-flight MR angiography. *Radiology* 1998;208:447-451.
68. Willinek WA, Born M, Simon B, et al. Time-of-flight MR angiography: comparison of 3.0-T imaging and 1.5-T imaging – initial experience. *Radiology* 2003;229:913-920.
69. Wilman AH, Riederer SJ, Huston J III, et al. Arterial phase carotid and vertebral artery imaging in 3-dimensional contrast-enhanced MR angiography by combining fluoroscopic triggering with an elliptical centric acquisition order. *Magn Reson Med* 1998;40:24-35.
70. Wiznitzer M, Masaryk TJ, Lewin J, et al. Parenchymal and vascular magnetic resonance imaging of the brain after extracorporeal membrane oxygenation. *Am J Dis Child* 1990;144:1323-1326.
71. Wiznitzer M, Ruggieri PM, Masaryk TJ, et al. Diagnosis of cerebrovascular disease in sickle cell anemia by magnetic resonance angiography. *J Pediatr* 1990;117:551-555.
72. Wiznitzer M, Masaryk TJ. Cerebrovascular abnormalities in pediatric stroke: assessment using parenchymal and angiographic magnetic resonance imaging. *Ann Neurol* 1991;29:585-589.

*Guidelines and standards are published annually with an effective date of October 1 in the year in which amended, revised or approved by the ACR Council. For guidelines and standards published before 1999, the effective date was January 1 following the year in which the guideline or standard was amended, revised, or approved by the ACR Council.

Development Chronology for this Guideline
 2000 (Resolution 11)
 Revised 2005 (Resolution 7)
 Amended 2006 (Resolution 35)